Multiple cancer

Adenoviral p53 (Ad-p53) for Recurrent Metastatic Cancers (MultiVir Study Ad-p53-002)

In this trial, Ad-p53 will be injected into cancers that have recurred or metastasized. The Ad-p53 experimental treatment will be combined with an approved cancer therapy termed anti-PD-1 or anti-PD-L1  that may have complementary immune stimulating activity.

Click link for more info

Studies performed in animal tumor models suggest that Ad-p53 may enhance the anti-tumor effects of anti-PD-1 and anti-PD-L1.